Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 6Phase 1/2 4Phase NA 2Phase 2/3 2Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 7Gynecologic 6Lymphoid 5Other hematologic neoplasm 3Head & Neck 3Breast 3Sarcoma 2Other solid neoplasm 2Genitourinary 2Dermatologic 2CNS 1

Conditions

Sarcoma 2Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Doxorubicin 7Radiotherapy 4Radiation 3Magnetic Resonance Spectroscopy 3Ifosfamide 3regorafenib 2Temozolomide 2Surgical Procedures, Operative 2Methotrexate 2Imatinib Mesylate 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2veliparib 1selinexor 1pirarubicin 1pazopanib 1niraparib 1merphos 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1capmatinib 1cabozantinib 1brigimadlin 1apatinib 1anlotinib 1Zoledronic Acid 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Drug Therapy × Sarcoma × Clear all
NCT02856048 2019-12-17

PRESOV

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Unknown
11 enrolled
LymphoidSarcoma

Lymphoma, Neoplasms, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Pierian Biosciences

Phase 2/3 Completed
150 enrolled
BreastGynecologicSarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡